JP2016503762A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503762A5
JP2016503762A5 JP2015547980A JP2015547980A JP2016503762A5 JP 2016503762 A5 JP2016503762 A5 JP 2016503762A5 JP 2015547980 A JP2015547980 A JP 2015547980A JP 2015547980 A JP2015547980 A JP 2015547980A JP 2016503762 A5 JP2016503762 A5 JP 2016503762A5
Authority
JP
Japan
Prior art keywords
ghb
pharmaceutical composition
salt
weight
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015547980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503762A (ja
JP6215347B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/074954 external-priority patent/WO2014093791A1/en
Publication of JP2016503762A publication Critical patent/JP2016503762A/ja
Publication of JP2016503762A5 publication Critical patent/JP2016503762A5/ja
Application granted granted Critical
Publication of JP6215347B2 publication Critical patent/JP6215347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015547980A 2012-12-14 2013-12-13 ガンマ‐ヒドロキシ酪酸塩組成物及び疾患の治療のためのその使用 Active JP6215347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737695P 2012-12-14 2012-12-14
US61/737,695 2012-12-14
PCT/US2013/074954 WO2014093791A1 (en) 2012-12-14 2013-12-13 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Publications (3)

Publication Number Publication Date
JP2016503762A JP2016503762A (ja) 2016-02-08
JP2016503762A5 true JP2016503762A5 (https=) 2017-08-17
JP6215347B2 JP6215347B2 (ja) 2017-10-18

Family

ID=49596603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547980A Active JP6215347B2 (ja) 2012-12-14 2013-12-13 ガンマ‐ヒドロキシ酪酸塩組成物及び疾患の治療のためのその使用

Country Status (24)

Country Link
US (9) US8591922B1 (https=)
EP (3) EP3335709B1 (https=)
JP (1) JP6215347B2 (https=)
KR (1) KR102180343B1 (https=)
CN (1) CN105025892B (https=)
AU (1) AU2013359114B2 (https=)
CA (1) CA2894876C (https=)
CY (2) CY1119918T1 (https=)
DK (2) DK2931268T3 (https=)
ES (2) ES2827005T3 (https=)
HR (1) HRP20201685T1 (https=)
HU (1) HUE051060T2 (https=)
IL (1) IL239355A (https=)
IN (1) IN342829B (https=)
LT (1) LT3335709T (https=)
MX (1) MX366681B (https=)
NO (1) NO3027826T3 (https=)
PL (1) PL2931268T3 (https=)
PT (2) PT2931268T (https=)
SG (1) SG11201504637TA (https=)
SI (1) SI3335709T1 (https=)
TR (1) TR201802271T4 (https=)
TW (2) TWI681770B (https=)
WO (1) WO2014093791A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3085941A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202135790A (zh) * 2019-12-24 2021-10-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Ghb給藥
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR102436227B1 (ko) * 2020-05-29 2022-08-24 주식회사 케이티앤지 기능성 물질이 코팅된 흡연물품용 팁페이퍼 및 상기 팁페이퍼의 코팅 방법
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程(武汉)有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) * 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
EP4228620A2 (en) 2020-10-16 2023-08-23 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
CA3209150A1 (en) * 2021-03-20 2022-09-29 Jayprakash Ajitsingh PARIHAR A process for the preparation of mixed oxybate salts and polymorphs thereof
US11877992B1 (en) 2021-06-07 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of learning disorders
US11877993B1 (en) 2021-06-23 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of psychological disorders
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20250073191A1 (en) 2022-01-11 2025-03-06 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
IL314441A (en) 2022-04-21 2024-09-01 Zevra Therapeutics Inc Gamma-Hydroxybutyrate providing compounds and processes for their production and use
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド 1晩1回の低ナトリウムオキシベート組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
US20080293698A1 (en) * 2005-05-16 2008-11-27 Joseph Johnson Methods and Compositions for Treating Arg
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8410304B2 (en) 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Similar Documents

Publication Publication Date Title
JP2016503762A5 (https=)
EP3375432B1 (en) Oral cavity composition
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
JP5108517B2 (ja) 治療活性剤、クエン酸または共役塩基、および二酸化塩素を含む安定化された組成物
JP5815969B2 (ja) 口腔用組成物
FR2665635A1 (fr) Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
CA3098108A1 (en) Compositions of o-glycosyl flavonoids
TWI902663B (zh) 外用組成物、析出物生成抑制方法
TWI815914B (zh) 外用組成物、析出物生成抑制方法
CA2532755A1 (en) Veterinary aqueous injectable suspensions containing florfenicol
WO2024234674A1 (zh) 药物液体组合物及其制备方法和应用
WO2013002382A1 (ja) ニコランジル含有医薬組成物
JP2017155031A (ja) 液状医薬製剤
JP5984531B2 (ja) 水性眼科組成物
JP2010105965A (ja) バンコマイシン製剤
JP5656368B2 (ja) 歯磨剤
CN110151574B (zh) 一种稳定性二氧化氯含漱液及其制备方法
JP2009143822A (ja) 内服液組成物
JP5922609B2 (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
JP7190538B2 (ja) 医薬組成物
CN103012192B (zh) 一种新型乙酰谷酰胺化合物及其药物组合物
JP2020002093A (ja) 乳化組成物
KR20140025369A (ko) 히알루론산 또는 히알루론산염을 포함하는 수용액
JP3983874B2 (ja) 口腔用組成物
JP5130601B2 (ja) 半固形状口腔用組成物